18275474. METHODS RELATING TO ANTI-IL-1 THERAPY AND ANTI-IL-6 THERAPY AND HYPERSENSITIVITY simplified abstract (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY)
Contents
- 1 METHODS RELATING TO ANTI-IL-1 THERAPY AND ANTI-IL-6 THERAPY AND HYPERSENSITIVITY
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 METHODS RELATING TO ANTI-IL-1 THERAPY AND ANTI-IL-6 THERAPY AND HYPERSENSITIVITY - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Original Abstract Submitted
METHODS RELATING TO ANTI-IL-1 THERAPY AND ANTI-IL-6 THERAPY AND HYPERSENSITIVITY
Organization Name
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventor(s)
Vivian E. Saper of Palo Alto CA (US)
Elizabeth D. Mellins of Palo Alto CA (US)
Jill Hollenbach of San Francisco CA (US)
METHODS RELATING TO ANTI-IL-1 THERAPY AND ANTI-IL-6 THERAPY AND HYPERSENSITIVITY - A simplified explanation of the abstract
This abstract first appeared for US patent application 18275474 titled 'METHODS RELATING TO ANTI-IL-1 THERAPY AND ANTI-IL-6 THERAPY AND HYPERSENSITIVITY
Simplified Explanation
The abstract of the patent application describes methods for treating subjects in need of IL-1 inhibitor therapy or IL-6 inhibitor therapy by determining the risk for drug-related hypersensitivity through HLA allele assays.
- Methods for treating subjects in need of IL-1 inhibitor therapy or IL-6 inhibitor therapy
- Assaying for the presence of certain HLA alleles to determine the risk for drug-related hypersensitivity
Potential Applications
The technology described in this patent application could be applied in the field of personalized medicine to tailor treatment plans for individuals based on their genetic makeup. It could also be used in drug development to identify patients who may be at risk for adverse reactions to certain medications.
Problems Solved
This technology helps to address the issue of drug-related hypersensitivity reactions in patients undergoing IL-1 or IL-6 inhibitor therapy. By identifying individuals who are at risk for these reactions, healthcare providers can take preventive measures to ensure patient safety.
Benefits
- Improved patient safety and outcomes in IL-1 and IL-6 inhibitor therapy - Personalized treatment plans based on genetic risk factors - Enhanced drug development processes through identification of at-risk populations
Potential Commercial Applications
"Genetic Risk Assessment for IL-1 and IL-6 Inhibitor Therapy: Market Opportunities and Challenges"
Possible Prior Art
One possible prior art could be studies or patents related to genetic testing for drug hypersensitivity reactions in other therapeutic areas. For example, there may be existing technologies or methods for predicting adverse drug reactions based on genetic markers.
=== What are the limitations of this technology in predicting drug-related hypersensitivity reactions? The technology relies on the identification of specific HLA alleles to predict drug-related hypersensitivity reactions. However, there may be other genetic or environmental factors that contribute to these reactions, which are not accounted for in this method.
=== How does this technology compare to existing methods for predicting drug-related hypersensitivity reactions? This technology offers a targeted approach by focusing on specific HLA alleles associated with hypersensitivity reactions to IL-1 and IL-6 inhibitors. Existing methods may use broader genetic markers or clinical assessments to predict adverse drug reactions.
Original Abstract Submitted
Provided herein are, inter alia, methods for treating subjects in need of an IL-1 inhibitor therapy or an IL-6 inhibitor therapy, and related methods. The methods include determining whether the subject is at risk for drug-related hypersensitivity by assaying for the presence of certain HLA alleles.
